JP MORGAN/CALL/MODERNA/145/0.1/17.01.25 Share Price

Warrant

DE000JL2JMK6

Delayed Börse Stuttgart 10:30:17 05/07/2024 pm IST
1 EUR -9.09% Intraday chart for JP MORGAN/CALL/MODERNA/145/0.1/17.01.25
Current month+1.85%
1 month-55.10%
Date Price Change
05/24/05 1 -9.09%
04/24/04 1.1 +10.00%
03/24/03 1 -3.85%
02/24/02 1.04 +1.96%
01/24/01 1.02 -5.56%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 10:30 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MODERNA, INC.
Issuer J.P. Morgan
WKN JL2JMK
ISINDE000JL2JMK6
Date issued 19/04/2023
Strike 145 $
Maturity 17/01/2025 (196 Days)
Parity 10 : 1
Emission price 4.1
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 4.1
Lowest since issue 0.36
Delta0.4x
Omega 4.218
Premium34.1x
Gearing10.54x
Moneyness 0.8025
Difference Strike 28.9 $
Difference Strike %+19.93%
Spread 0.02
Spread %1.94%
Theoretical value 1.010
Implied Volatility 56.20 %
Total Loss Probability 74.80 %
Intrinsic value 0.000000
Present value 1.010
Break even 155.94 €
Theta-0.03x
Vega0.03x
Rho0.02x

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116 USD
Average target price
145.9 USD
Spread / Average Target
+25.79%
Consensus